scPharmaceuticals is a pharmaceutical company focused on developing and commercializing products that have the potential to improve the delivery of infused therapies and develop patient care. Co.'s product, FUROSCIX®, consists of its formulation of furosemide delivered via West Pharmaceutical Services, Inc.'s on-body infusor, and is used for the treatment of congestion due to fluid overload in adults with New York Heart Association Class II/III chronic heart failure. FUROSCIX is a subcutaneous loop diuretic that delivers intravenous equivalent diuresis at home. The SCPH average annual return since 2017 is shown above.
The Average Annual Return on the SCPH average annual return since 2017 page and across the coverage universe of our site,
is a measure of the annualized return over the past ten years (or specified start date) for a given investment
(up to the end of prior trading session recorded). Arguably, choosing ten years for a measurement
period is on the one hand completely arbitrary, but on the other hand provides a sufficiently long window
to capture long-term trends.
Thus, researching Average Annual Returns is good practice for investors — whether SCPH average annual return since 2017 or other benchmarks/peers
— and when doing so it is also important to factor in dividends, because a financial instrument's annualized return is
more than just the change in price if that instrument pays a dividend or coupon. Our website aims to empower investors
by performing the SCPH average annual return calculation with any dividends reinvested as applicable (on ex-dates).
|
Free SCPH Email Alerts:
Video: Don't Forget Dividends in Average Annual Return!
